Antimalarial Drugs Market by Drug Class and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019–2026

Antimalarial Drugs Market by Drug Class and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019–2026

  • March 2020 •
  • 193 pages •
  • Report ID: 5897573 •
  • Format: PDF
Antimalarial Drugs Market by Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, and Others) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce & Other Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019–2026

The global antimalarial drugs market accounted for $711,360 thousand in 2018 and is expected to reach $1,019,396 thousand by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Malaria is caused by the transmission of parasites belonging to genus plasmodium. These parasites are transmitted through the bite of female Anopheles mosquito, which then get lodged into liver. These parasites grow in liver and multiply to further invade the red blood cells where these parasites mature and rupture the blood cell to form merozoites. These merozoites then invade other red blood cells,causing symptoms such as high fever, fatigue, dizziness, and others.Thus, malaria is highly fatal if left untreated for a long period of time. Therefore, the drugs used in the treatment of malaria are called as antimalarial drugs. Furthermore, there are different types of antimalarial drugs available in the market, which include quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. In addition, these drugs can be purchased on prescription from different type of pharmacies such as hospital and retail pharmacies. Moreover, these drugs are also available on e-commerce websites.
The major factor that drives the growth of the antimalarial drugs market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness regarding healthcare in developing countries is a major factor that restrains the growth of the antimalarial drugs market. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for the market expansion during the forecast period.
The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S. and Canada), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global antimalarial drugsmarket trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments
• By Drug Class
o Quinine
o Chloroquine
o Proguanil
o Mefloquine
o Pyrimethamine
o Others
• By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o E-Commerce & Other Distribution Channel

• By Region
o North America
- U.S.
- Canada
o Europe
- Germany
- UK
- Rest of Europe
o Asia-Pacific
- China
- India
- Rest of Asia-Pacific
o LAMEA
- Africa
- Rest of LAMEA
• List of key players profiled in the report:
• Alvizia Healthcare Pvt. Ltd.
• Bayer AG
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
• Zydus Cadila

LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
• Cipla Limited
• Ajanta Pharma